AbCellera, Denali to discover neurological disease antibodies

AbCellera will generate panels of antibodies against up to eight neurology targets selected by Denali using AbCellera’s high-throughput, ultra-deep single-cell immune profiling platform.

Denali Therapeutics Inc. (NASDAQ:DNLI) will pay a technology access fee and research funding. AbCellera Biologics Inc. (Vancouver, B.C.) is eligible for development and commercial milestones, plus royalties...